Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Free Report) has been given a consensus rating of “Hold” by the twelve analysts that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $36.36.
Several brokerages recently commented on TNDM. Stifel Nicolaus raised Tandem Diabetes Care from a “hold” rating to a “buy” rating and raised their target price for the stock from $24.00 to $37.00 in a research report on Tuesday, March 26th. Citigroup lifted their target price on Tandem Diabetes Care from $25.00 to $31.00 and gave the company a “neutral” rating in a research report on Friday, March 15th. Finally, StockNews.com raised Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research report on Thursday, March 21st.
View Our Latest Stock Report on Tandem Diabetes Care
Institutional Investors Weigh In On Tandem Diabetes Care
Tandem Diabetes Care Trading Up 0.3 %
TNDM opened at $35.41 on Monday. Tandem Diabetes Care has a 52-week low of $13.82 and a 52-week high of $43.51. The company has a quick ratio of 3.02, a current ratio of 3.83 and a debt-to-equity ratio of 0.91. The firm has a market capitalization of $2.32 billion, a P/E ratio of -10.29 and a beta of 1.08. The firm’s 50 day moving average is $26.97 and its 200-day moving average is $23.67.
Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) last posted its quarterly earnings data on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Tandem Diabetes Care had a negative return on equity of 31.48% and a negative net margin of 29.77%. The company had revenue of $196.80 million during the quarter, compared to analyst estimates of $204.86 million. Analysts expect that Tandem Diabetes Care will post -1.62 EPS for the current fiscal year.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.
See Also
- Five stocks we like better than Tandem Diabetes Care
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- MarketBeat Week in Review – 3/25-3/29
- What is a buyback in stocks? A comprehensive guide for investors
- 3 Value Stocks Too Small For Buffett’s Portfolio
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.